Irbesartan/Hydrochloorthiazide Xiromed

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hydrochloorthiazide Xiromed, is an Angiotensin II receptor blocker / Thiazide diuretic presented as a strength/form unknown for oral use. It is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Irbesartan/Hydrochloorthiazide Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance.

Irbesartan/Hydrochlorothiazide is an antihypertensive agent that lowers elevated blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications in patients with high blood pressure.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances such as low potassium - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute renal failure - Hyperkalemia when combined with potassium‑sparing agents - Allergic reactions including rash or angioedema - Liver enzyme elevations - Pancreatitis (rare)

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: monitor potassium and sodium levels due to diuretic effect. - Diabetes mellitus: watch for changes in blood glucose control. - Hepatic impairment: use with caution in severe liver disease. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase the risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous elevations in serum potassium.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive efficacy and affect renal function. - Lithium: concurrent use may raise lithium levels, leading to toxicity. - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect may cause symptomatic hypotension.